1-3 of 3
Riccardo Colombo
Close
Sort by
Journal Articles

Debio 1562M, a Next Generation Antibody Drug Conjugate (ADC) Targeting CD37 for AML and MDS Treatment

Lisa Ivanschitz, Josée Hue-Perron, Léo Marx, Marie-Claude Roubaudi-Fraschini, Caroline Peet, Nathalie Bellocq, Riccardo Colombo, Karilyn T. Larkin, Esthela Artiga
Journal: Blood
Blood (2023) 142 (Supplement 1): 1542.
https://doi.org/10.1182/blood-2023-180767
Published: 2023
Journal Articles

Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I

Artur Gontarewicz, Stefan Balabanov, Gunhild Keller, Riccardo Colombo, Alessio Graziano, Enrico Pesenti, Daniel Benten, Carsten Bokemeyer, Walter Fiedler, Jürgen Moll, Tim H. Brümmendorf
Journal: Blood
Blood (2008) 111 (8): 4355–4364.
https://doi.org/10.1182/blood-2007-09-113175
Published: 2008
Journal Articles

Simultaneous Targeting of Aurora Kinases and Bcr-Abl by the Small Molecule Inhibitor PHA-739358 Is Effective in Imatinib-Resistant Mutations Including T315I.

Artur Gontarewicz, MD, Stefan Balabanov, M.D., Ph.D., Gunhild Keller, M.D., Riccardo Colombo, Ph.D., Alessio Graziano, Ph.D, Carsten Bokemeyer, M.D., Walter Fiedler, M.D., Jurgen Moll, Ph.D., Tim Brummendorf, M.D.
Journal: Blood
Blood (2007) 110 (11): 1042.
https://doi.org/10.1182/blood.V110.11.1042.1042
Published: 2007